Eterna Therapeutics Inc. (ERNA)
After hours:
| Previous Close | 1.7300 |
| Open | 1.7300 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.7300 - 1.8900 |
| 52 Week Range | 0.8400 - 3.4500 |
| Volume | |
| Avg. Volume | 8,374 |
| Market Cap | 9.684M |
| Beta (5Y Monthly) | 8.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.0800 |
| Earnings Date | May 06, 2024 - May 10, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireEterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors
CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Peter Cicala, JD, to its Board of Directors. “Peter Cicala has deep experience in the biotechnology and pharmaceutical industry, from start-ups to big pharma, and from bench to commercialization,” said
- GlobeNewswire
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced that Eterna’s Board of Directors granted a non-qualified stock option to purchase 1,685,218 shares of Eterna’s common stock (the “Stock Option”) to its new President and Chief Executive Officer, Sanjeev Luther, effective
- GlobeNewswire
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer
CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, has appointed Sanjeev Luther as President and Chief Executive Officer and a member of the company's Board of Directors, effective January 1, 2024. Mr. Luther will replace Matt Angel, Ph.D., the current President and Chief Executive Offic
